PPP tipping point

For the past five years, BioCentury Innovations has tracked the formation of new public-private partnerships (PPPs) to follow how biotechs and pharmas are using research partnerships to access academic innovation. While the 2015 data show the trend is still alive with 236 new deals across the world, the numbers also suggest the earlier enthusiasm has been tempered and the heyday of consortia has passed.

PPPs - defined here as preclinical collaborations, outside of straightforward licensing deals, that include at least one organization from the private sector, and at least one that is publicly funded - have gained status as one of the principal means by which pharmas feed their pipeline and keep a hand in cutting-edge research. ...